We are live on ! Find out more
ASBPW

Aspire Biopharma Warrant
ASBPW

40 hedge funds and large institutions have $1.15M invested in Aspire Biopharma Warrant in 2023 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

14% more funds holding

Funds holding: 35 → 40 (+5)

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

56% less capital invested

Capital invested by funds: $2.63M → $1.15M (-$1.48M)

Holders
40
Holders Change
+5
Holders Change %
+14.29%
% of All Funds
0.63%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
3
Reduced
3
Closed
2
Calls
$2.12M
Puts
–
Net Calls
+$2.12M
Net Calls Change
+$5K

Top Buyers

Rank Fund Capital Flow
1
HIM
HGC Investment Management
Ontario, Canada
+$3.67K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.25K
3
Walleye Capital
Walleye Capital
New York
+$1.17K
4
EFI
EHP Funds Inc
Canada
+$918
5
PC
Periscope Capital
Ontario, Canada
+$918

Top Sellers

Rank Fund Capital Flow
1
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$8.36K
2
DCM
Difesa Capital Management
New York
-$3.13K
3
PMAM
Picton Mahoney Asset Management
Ontario, Canada
-$918
4
AA
AQR Arbitrage
Connecticut
-$133
5
CS
Clear Street
New York
-$58
Name Holding Trade Value Shares
Change 		Change in
Stake
MP
1
Mangrove Partners
Connecticut
$652K – – –
PC
2
Periscope Capital
Ontario, Canada
$73.2K +$918 +25,000 +2%
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$52.6K – – –
LA
4
Linden Advisors
New York
$49.5K – – –
SCM
5
Saba Capital Management
New York
$49.3K – – –
AA
6
AQR Arbitrage
Connecticut
$32.4K -$133 -3,612 -0.6%
SC
7
Sculptor Capital
New York
$27.5K – – –
Verition Fund Management
8
Verition Fund Management
Connecticut
$21.7K – – –
WAM
9
Wolverine Asset Management
Illinois
$20.1K – – –
SFM
10
Spartan Fund Management
Canada
$18.7K +$66 +1,804 +1%
KC
11
Kepos Capital
New York
$18K +$12.8K +350,000 New
Barclays
12
Barclays
United Kingdom
$17.5K – – –
TCA
13
Taconic Capital Advisors
New York
$15K – – –
D.E. Shaw & Co
14
D.E. Shaw & Co
New York
$10K – – –
RCM
15
Radcliffe Capital Management
Pennsylvania
$9K – – –
CCM
16
Context Capital Management
California
$9K – – –
SRCM
17
Sage Rock Capital Management
New York
$8.02K – – –
Nomura Holdings
18
Nomura Holdings
Japan
$7.5K – – –
PAMP
19
Polar Asset Management Partners
Ontario, Canada
$6.94K – – –
LP
20
LMR Partners
United Kingdom
$6.26K – – –
WA
21
Whitebox Advisors
Minnesota
$6.26K – – –
HIM
22
HGC Investment Management
Ontario, Canada
$6K +$3.67K +100,000 New
KL
23
KIM LLC
Kansas
$5.5K – – –
HCM
24
Highbridge Capital Management
New York
$4.6K – – –
CCM
25
CAAS Capital Management
New York
$3.76K – – –
1
2

ASBPW Hedge Fund Activity: Q2 2023 in Review

40 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma Warrant (ASBPW) for Q2 2023, worth a combined $1.15M — down 56% from $2.63M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new ASBPW positions and 2 closed out — a net gain of 5 holders — while 3 added to existing stakes and 3 trimmed.

The largest buyer was HGC Investment Management, opening a new position worth an estimated $3.67K. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $8.36K sold.

  • 40 institutional investors held Aspire Biopharma Warrant (ASBPW) as of Q2 2023, up from 35 in Q1 2023.
  • Funds reported $1.15M of Aspire Biopharma Warrant stock for Q2 2023, down 56% quarter-over-quarter.
  • 7 funds opened new Aspire Biopharma Warrant positions in Q2 2023 and 2 closed out, a net change of +5 holders.
  • The largest Aspire Biopharma Warrant buyer in Q2 2023 was HGC Investment Management, an estimated $3.67K added.
  • The largest Aspire Biopharma Warrant seller in Q2 2023 was Balyasny Asset Management, an estimated $8.36K sold.

Based on aggregated 13F filings for Q2 2023.